EDITORIAL
Towards a chemotherapy-free future in breast cancer?
Recent studies support treatment optimisation for improving patients’ quality of life, but its implementation in clinical practice remains limited
ESMO BREAST CANCER 2026
SERD therapy demonstrates robust anti-proliferative activity in young patients with ER-positive/HER2-negative early breast cancer
Encouraging results with giredestrant support the future use of SERD-based endocrine strategies in this setting
Chemotherapy-free adjuvant treatment preserves quality of life in HER2-positive early breast cancer
A pathological complete response-guided approach enables treatment optimisation in a selected population with HER2-positive breast cancer in the PHERGain-2 study
Liquid biopsy has the potential to improve patients’ lives across the entire spectrum of breast cancer
The 2026 ESMO Breast Cancer Awardee, Daniel F. Hayes, reflects on the future of biomarker research in the field
AI & DIGITAL ONCOLOGY
Customised app shows promise for monitoring prostate cancer patients in real-time
A pilot study reports high levels of acceptance and compliance despite an older patient population
Why AI-powered trial matching alone will not fix oncology trial recruitment
AI-powered trial matching helps identify relevant trials faster, but recruitment often fails beyond the algorithm. Limited cross-site trial discovery, outdated recruitment information and fragmented referral pathways continue to prevent potentially eligible patients from participating in relevant trials.
Can AI chatbots effectively support patients with cancer during treatments?
Early findings suggest potential benefits in symptom monitoring, but highlight usability challenges and added burden on clinical workflows
FROM GUEST EDITORS
A driving force to accelerate drug development
Fostering academic clinical research is one of the ESMO’s priorities, and artificial intelligence may be a major driver
Why clinical practice guidelines matter even more in rare cancers
A recent EURACAN survey highlights a high uptake of recommendations from medical oncologists, potentially leading to improved patients’ survival
Optimising cancer care to improve clinical outcomes and sustainability
From chronotherapy to immunotherapy resistance, refining when and for whom treatments work is becoming central to making oncology sustainable
OPINIONS
Can digital tools improve personalised support for adolescents and young adults with cancer?
Ivana Bozovic-Spasojevic
The management of invasive lobular breast cancer is evolving
Rinath Jeselsohn
Phenotypic profiling in pancreatic cancer: promise meets practical limits
Alejandro González Sánchez
Novel emerging targets, new treatment opportunities
Jonathan Lim
Overcoming resistance to immunotherapy in NSCLC?
Alessandra Curioni Fontecedro
OPINIONS
Can digital tools improve personalised support for adolescents and young adults with cancer?
Ivana Bozovic-Spasojevic
The management of invasive lobular breast cancer is evolving
Rinath Jeselsohn
Phenotypic profiling in pancreatic cancer: promise meets practical limits
Alejandro González Sánchez
Novel emerging targets, new treatment opportunities
Jonathan Lim
Overcoming resistance to immunotherapy in NSCLC?
Alessandra Curioni Fontecedro